• China SXT Pharmaceuticals entered private placement with non-U.S. investors on May 1, 2026, raising gross proceeds of $3.5 million.
• Deal issued 3,500,000 Class A ordinary shares, no par value, alongside 3,500,000 warrants exercisable at $1 per share.
• Warrants became exercisable on issuance, expire five years from issuance, include customary anti-dilution adjustments, allow cash or cashless exercise.
• Offering closed May 2, 2026; net proceeds earmarked for working capital, general corporate purposes.
• Securities sold in unregistered transaction under Regulation S.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China SXT Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-051679), on May 04, 2026, and is solely responsible for the information contained therein.